Research programme - kinase-inhibiting RNase attenuators - OptiKiraAlternative Names: Cell death inhibitors - OptiKira; ERN1 protein inhibitors - OptiKira; Small molecule therapeutics - OptiKira
Latest Information Update: 06 Feb 2015
At a glance
- Originator OptiKira
- Class Small molecules
- Mechanism of Action Cell death inhibitors; ERN1 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus; Retinitis pigmentosa
- Research Amyotrophic lateral sclerosis